StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Puma Biotechnology total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Puma Biotechnology's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $22.52M, down 66.4% from the year before. The highest annual figure on record is $99.66M in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$22.52M-66.4%
FY2024Dec 31, 2024$67.05M-32.7%
FY2023Dec 31, 2023$99.66M+1.4%
FY2022Dec 31, 2022$98.31M+1.3%
FY2021Dec 31, 2021$97.09M-1.2%
FY2020Dec 31, 2020$98.31M+3.5%
FY2019Dec 31, 2019$94.96M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$11.28M-79.8%
Q4 FY2025Dec 31, 2025$22.52M-66.4%
Q3 FY2025Sep 30, 2025$33.72M-56.8%
Q2 FY2025Jun 30, 2025$44.87M-49.6%
Q1 FY2025Mar 31, 2025$55.98M-44.0%
Q4 FY2024Dec 31, 2024$67.05M-32.7%
Q3 FY2024Sep 30, 2024$78.08M-21.4%
Q2 FY2024Jun 30, 2024$89.06M-10.0%
Q1 FY2024Mar 31, 2024$100.02M+1.4%
Q4 FY2023Dec 31, 2023$99.66M+1.4%
Q3 FY2023Sep 30, 2023$99.30M+1.3%
Q2 FY2023Jun 30, 2023$98.95M+1.3%
Q1 FY2023Mar 31, 2023$98.62M+1.3%
Q4 FY2022Dec 31, 2022$98.31M+1.3%
Q3 FY2022Sep 30, 2022$97.99M+1.2%
Q2 FY2022Jun 30, 2022$97.68M-2.4%
Q1 FY2022Mar 31, 2022$97.38M-1.8%
Q4 FY2021Dec 31, 2021$97.09M-1.2%
Q3 FY2021Sep 30, 2021$96.80M-0.6%
Q2 FY2021Jun 30, 2021$100.14M+5.4%
Q1 FY2021Mar 31, 2021$99.20M–
Q4 FY2020Dec 31, 2020$98.31M–
Q3 FY2020Sep 30, 2020$97.43M–
Q4 FY2019Dec 31, 2019$94.96M–

More Puma Biotechnology figures

See a number that looks wrong?